Cirrhosis News and Research

Latest Cirrhosis News and Research

Researchers develop new MRI-based technique to better detect NAFLD in children

Between 5 and 8 million children in the United States have nonalcoholic fatty liver disease (NAFLD), yet most cases go undiagnosed. To help address this issue, researchers at UC San Diego School of Medicine have developed a new magnetic resonance imaging (MRI)-based technique to help clinicians and researchers better detect and evaluate NAFLD in children.

6 Feb 2015

Chemotherapy or immunosuppressive treatment may reactivate HBV

Individuals previously infected with the hepatitis B virus (HBV) who receive chemotherapy or immunosuppressive treatment may be at risk of reactivating the disease according to a summary of report from the Emerging Trends Conference, "Reactivation of Hepatitis B," and published in Hepatology, a journal of the American Association for the Study of Liver Diseases.

6 Feb 2015

AbbVie releases Phase 3 results from all-oral OBV/PTV/r treatment for GT1b chronic HCV infection

AbbVie released top-line Phase 3 results for its investigational, all-oral, ribavirin (RBV)-free, two direct-acting antiviral treatment with ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) in patients with genotype 1b (GT1b) chronic hepatitis C virus (HCV) infection in Japan.

31 Jan 2015

Farnesoid-X receptor could play key role in hepatobiliary and gastrointestinal disorders

The farnesoid-X receptor (FXR), also known as the chief regulator of bile acid metabolism, is thought to play a role in some hepatobiliary and gastrointestinal disorders.

30 Jan 2015

Age and HBsAg level predict NA-induced HBeAg seroconversion durability

The combination of age and baseline hepatitis B s-antigen level can help predict hepatitis B virus relapse in patients who achieve hepatitis B e-antigen loss or seroconversion following nucleos(t)ide analogue (NA) treatment, researchers report.

28 Jan 2015

Alcohol drinking pattern influences risk of cirrhosis

Approximately 170,000 people die from alcoholic cirrhosis of the liver in Europe every year. Although alcohol is the most important risk factor, less is known about the significance of different patterns of drinking. Currently scientists believe that cirrhosis is a function of the volume of alcohol consumed irrespective of patterns of drinking. Investigators have now established that alcohol drinking pattern has a significant influence on the risk of cirrhosis and that daily drinking increases that risk compared with drinking less frequently.

27 Jan 2015

Using breath tests to diagnose liver diseases: an interview with Larry Cohen

It was back in the 1960s that scientists first started to understand that breath could be used to find out different things about diseases and other factors. I’m sure you’re familiar with alcohol breath testing, which was patented back in the ‘50s and has been used since the ‘60s.

19 Jan 2015

AbbVie gets European Commission's approval to market VIEKIRAX + EXVIERA for HCV treatment

AbbVie announced that the European Commission has granted marketing authorizations for its all-oral, short-course, interferon-free treatment of VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA (dasabuvir tablets). The treatment has been approved with or without ribavirin (RBV) for patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, including those with compensated liver cirrhosis, HIV-1 co-infection, patients on opioid substitution therapy and liver transplant recipients.

16 Jan 2015

EMA validates Synageva's sebelipase alfa MAA for LAL Deficiency

Synageva BioPharma Corp., a biopharmaceutical company developing therapeutic products for rare disorders, today announced validation by the European Medicines Agency of the Marketing Authorization Application for sebelipase alfa for LAL Deficiency.

23 Dec 2014

Abbvie’s HOLKIRA PAK for chronic genotype 1 Hepatitis C treatment receives Health Canada approval

AbbVie receives Health Canada approval for HOLKIRA PAK (ombitasvir/paritaprevir/ritonavir film-coated tablets; dasabuvir film-coated tablets), an all-oral, short-course (12 weeks for the majority of patients), interferon-free treatment, with or without ribavirin (RBV), for the treatment of patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, including those with cirrhosis.

23 Dec 2014

Study underscores the importance of appropriate testing, support and care for HCV patients

A new study shows that many patients infected with the hepatitis C virus (HCV) are lost during different stages of health care to manage the disease.

23 Dec 2014

FDA approves AbbVie's VIEKIRA PAK for treatment of patients with GT1 HCV infection

The U.S. Food and Drug Administration has approved AbbVie's VIEKIRA PAK, an all-oral, interferon-free treatment, with or without ribavirin (RBV), for the treatment of patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection, including those with compensated cirrhosis.

21 Dec 2014

New analysis finds global improvements in life expectancy

Global life expectancy increased by 5.8 years in men and 6.6 years in women between 1990 and 2013, according to a major new analysis from the Global Burden of Disease Study 2013 (GBD 2013).

19 Dec 2014

New study highlights importance of generating awareness about HCV testing, support and care

A new study shows that many patients infected with the hepatitis C virus (HCV) are lost during different stages of health care to manage the disease. This real-life' view of the HCV patient care continuum in a major U.S. urban area is published in Hepatology, a journal of the American Association for the Study of Liver Diseases, and highlights the importance of generating awareness among clinicians and at-risk groups about appropriate HCV testing, referral, support and care.

18 Dec 2014

Study provides new evidence for anti-cirrhotic effects of GENFIT's GFT505

GENFIT, a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions in metabolic and inflammatory diseases, that notably affect the liver or the gastrointestinal system, today announces that a recent study provides new evidence for anti-cirrhotic effects of GFT505 in the context of NASH.

17 Dec 2014

Lilly receives FDA approval for CYRAMZA (ramucirumab)

Eli Lilly and Company has received its third U.S. Food and Drug Administration approval for CYRAMZA (ramucirumab).

16 Dec 2014

Added benefit of daclatasvir drug not proven for chronic hepatitis C infection

The drug daclatasvir (trade name Daklinza) has been available since August 2014 for the treatment of adults with chronic hepatitis C (CHC) infection. The German Institute for Quality and Efficiency in Health Care examined in a dossier assessment whether this new drug offers an added benefit over the appropriate comparator therapy.

11 Dec 2014

Loyola University Medical Center opens center to provide treatments for diseased heart valves

Loyola University Medical Center has opened a multidisciplinary Valve Center that offers patients a full range of treatments for diseased heart valves.

10 Dec 2014

Scientists review HBV-associated tumor microenvironment in hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is one of the few cancers in which a continued increase in incidence has been observed over recent years. Globally, there are approximately 750,000 new cases of liver cancer reported each year. Importantly, population-based studies show that HCC ranks as the third leading cause of cancer-related deaths worldwide.

4 Dec 2014

Joint therapy to counter HIV and HCV increases chance of success

A Spanish researcher has collaborated on a mathematical analysis, recently published in the journal 'Science Translational Medicine', which concludes that joint therapy to counter HIV in patients who also have hepatitis C increases the chance of success in the fight against both infections. Between eight and nine million people worldwide simultaneously suffer from AIDS and hepatitis C.

3 Dec 2014

Cirrhosis News and Research

Latest Cirrhosis News and Research

Researchers develop new MRI-based technique to better detect NAFLD in children

Chemotherapy or immunosuppressive treatment may reactivate HBV

AbbVie releases Phase 3 results from all-oral OBV/PTV/r treatment for GT1b chronic HCV infection

Farnesoid-X receptor could play key role in hepatobiliary and gastrointestinal disorders

Age and HBsAg level predict NA-induced HBeAg seroconversion durability

Alcohol drinking pattern influences risk of cirrhosis

Using breath tests to diagnose liver diseases: an interview with Larry Cohen

AbbVie gets European Commission's approval to market VIEKIRAX + EXVIERA for HCV treatment

EMA validates Synageva's sebelipase alfa MAA for LAL Deficiency

Abbvie’s HOLKIRA PAK for chronic genotype 1 Hepatitis C treatment receives Health Canada approval

Study underscores the importance of appropriate testing, support and care for HCV patients

FDA approves AbbVie's VIEKIRA PAK for treatment of patients with GT1 HCV infection

New analysis finds global improvements in life expectancy

New study highlights importance of generating awareness about HCV testing, support and care

Study provides new evidence for anti-cirrhotic effects of GENFIT's GFT505

Lilly receives FDA approval for CYRAMZA (ramucirumab)

Added benefit of daclatasvir drug not proven for chronic hepatitis C infection

Loyola University Medical Center opens center to provide treatments for diseased heart valves

Scientists review HBV-associated tumor microenvironment in hepatocellular carcinoma

Joint therapy to counter HIV and HCV increases chance of success

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Cirrhosis News and Research

Latest Cirrhosis News and Research

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in